Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 9/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215343 | 0.80 | LIPG (0.43) | NR1I3PDK1 | |
| SCHEMBL1397622 | 0.79 | SIGMAR1 (0.41) | NR1I3SIGMAR1ROCK1CYP1A2CYP2D6 | |
| SCHEMBL1397602 | 0.78 | SIGMAR1 (0.41) | NR1I3SIGMAR1ROCK1CYP1A2CYP2D6 | |
| SCHEMBL3201412 | 0.68 | LIPG (0.44) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3194445 | 0.67 | LIPG (0.44) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5175700 | 0.66 | CYP2D6 (0.55) | NR1I3SIGMAR1ROCK1CYP1A2CYP2D6 | |
| SCHEMBL3940149 | 0.63 | CYP1A2 (0.60) | NR1I3SIGMAR1ROCK1CYP1A2CYP2D6 | |
| SCHEMBL5187832 | 0.63 | CYP1A2 (0.53) | NR1I3SIGMAR1ROCK1CYP1A2CYP2D6 | |
| SCHEMBL1397578 | 0.63 | L3MBTL1 (0.42) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3390640 | 0.63 | CYP1A2 (0.56) | NR1I3SIGMAR1ROCK1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674815-B2 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | claimed |
| EP-2007726-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7674815-B2 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2007726-A2 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007090749-A2 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | CYP2C19, CYP2C9, CYP3A43 | NR1I3 762/4885SIGMAR1 485/4885ROCK1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.